Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.


Clinical Pharmacology & Therapeutics (CPT)
Oncology
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
May 13, 2009
2009
DOI: 10.1038/clpt.2009.68
American Heart Association Journal
Neuroscience
Stroke
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke
October 16, 2003
2003
DOI: 10.1161/01.STR.0000092527.33910.89
No results found.
There are no results with this criteria. Try changing your search.